Glaritus 100 Iu/ml Injection 3 ml

Glaritus 100 Iu/ml Injection 3 ml is a prescription based long-acting type of insulin with active ingredient Insulin Glargine (100IU). It is used in the treatment of type 1 and 2 diabetes mellitus in both adults & children. Glaritus give a stable level of insulin in the body for an entire day and helps to control blood sugar levels.

This medicine also helps to prevent complications associated with diabetes. Healthcare provider will teach the proper way of injecting it under the skin correctly. It can be prescribed alone or in combination with fast-acting insulin or other diabetes medicines.

• Diabetes

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Glaritus 100 Iu/ml Injection 3 ml   also causes some adverse impact on the body, most of which resolve without any medical attention.
Some common side effects include:

• Edema (swelling)
• Allergic reaction
• Injection site reactions (pain, swelling, redness)
• Rash
• Lipodystrophy (skin thickening or pits at the injection site)
• Itching
• Weight gain
• Hypoglycemia (low blood glucose level)

Seek medical attention in case of any unusual or severe side effects immediately.

• Dosage of the Glaritus 100 Iu/ml Injection 3 ml decide according to the type of diabetes and overall health condition of the patient. This injection can be administered by a doctor or nurse or your care giver may be taught on how to use this medicine at home.
• In case of an overdose, the doctor will provide emergency medical treatment. Do not stop or change the dose without informing your doctor.
  
  

• Glaritus 100IU/ml Injection 3ml is a prescription based long-acting type of insulin. It helps to treat type 1 & type 2 diabetes by providing consistent and all-day sugar control.
• It works like the body's natural insulin. Insulin facilitates the reuptake of sugar in muscle and fat cells as well as suppresses sugar production in the liver.
  
  

• Dunn, C. J., Plosker, G. L., Keating, G. M., McKeage, K., & Scott, L. J. (2003). Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs, 63(16), 1743-1778. https://pubmed.ncbi.nlm.nih.gov/12904090/
• Upadhayay, D. K., Palaian, S., Prabhu, M., Shankar, P. R., & Mishra, P. (2008). Insulin glargine. Journal of Institute of Medicine Nepal, 30(1), 72-77. https://www.nepjol.info/index.php/JIOM/article/view/1385
• Vrebalov Cindro, P., Krnić, M., Modun, D., Vuković, J., Tičinović Kurir, T., Kardum, G. ... & Bukić, J. (2022). Comparison of the impact of insulin degludec U100 and insulin glargine U300 on glycemic variability and oxidative stress in insulin-naive patients with type 2 diabetes mellitus: Pilot study for a randomized trial. JMIR formative research, 6(7), e35655. https://pubmed.ncbi.nlm.nih.gov/35802405/
• Heise, T., Hoevelmann, U., Nosek, L., Hermanski, L., Bøttcher, S. G., & Haahr, H. (2015). Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert opinion on drug metabolism & toxicology, 11(8), 1193-1201. https://pubmed.ncbi.nlm.nih.gov/26086190/
• Rosenstock, J., Schwartz, S. L., Clark Jr, C. M., Park, G. D., Donley, D. W., & Edwards, M. B. (2001). Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes care, 24(4), 631-636. https://pubmed.ncbi.nlm.nih.gov/11315821/